Volume 14 Supplement 1
Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension
© Hoffmann et al; licensee BioMed Central Ltd. 2013
Published: 29 August 2013
The cytoprotective NO/sGC/cGMP-signalling pathway is impaired under oxidative stress conditions as observed for cardiovascular diseases due to oxidation and subsequent loss of the prosthetic sGC heme group [1, 2]. Thus, the pool of heme free sGC is increased under pathological conditions. The unique property of sGC activators such as cinaciguat (BAY 58—2667) to selectively activate heme free sGC allows to target the disease associated form of sGC. In this study a therapeutic effect of long-term activation of heme free sGC was investigated in an experimental model of salt sensitive hypertension.
Material and methods
Male Dahl/ss rats, 7 weeks of age, were randomly allocated into two groups: control group (n=20) receiving a high salt diet containing 8 % NaCl, cinaciguat group (n=17) receiving 1000 ppm cinaciguat in the high salt diet. 6 h urine samples were collected at week 19. Systolic blood pressure and heart rate were measured using tail-cuff at week 0, 6, 9, 12, 15 and 21. High resolution echocardiography was performed at week 20. The study was terminated at week 21 (50 % survival of the control group). Plasma and urine parameters were analyzed using a Multichannel Autoanalyzer. ANP and cGMP were analysed using radioimmunoassay kits. Plasma and urine concentrations of osteopontin (OPN) were determined using immunoassay kits. Gene expression of biomarkers was analysed by qRT-PCR.
Cinaciguat highly significantly improved survival (Χ2=8) compared to control. Increase in blood pressure and heart rate was significantly lower in cinaciguat treated rats than in control rats. M-mode echocardiography showed increased fractional shortening and a higher diameter increase of the septum between systole and diastole. Urine concentrations of urea and protein and plasma levels of uric acid were reduced in cinaciguat compared to control. Cinaciguat prevented the increase in expression of pro-fibrotic and pro-inflammatory biomarkers in kidney and left ventricle compared to control. Histopathological examination of organs from deceased animals revealed that especially fibrotic and inflammatory events in the heart and kidney were the cause of death. These pathological lesions were markedly decreased in cinaciguat treated animals.
The data clearly shows that long-term activation of heme free sGC with cinaciguat leads to cardio-renal protection demonstrated by reduced mortality, improved cardiac and renal function, lower increase in blood pressure and reduced inflammatory and fibrotic events. These results underline the promising potential of sGC activators to treat cardiovascular diseases by targeting the heme free form of sGC.
- Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schröder H, Stahl E, Steinke W, Wunder F: NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002, 136: 773-783. 10.1038/sj.bjp.0704778.PubMed CentralView ArticlePubMedGoogle Scholar
- Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Müller-Esterl W, Schmidt HH: Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006, 116: 2552-2561. 10.1172/JCI28371.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.